Aclaris Therapeutics Statistics
Total Valuation
ACRS has a market cap or net worth of $635.47 million. The enterprise value is $446.67 million.
Important Dates
The last earnings date was Thursday, May 7, 2026, before market open.
| Earnings Date | May 7, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ACRS has 139.66 million shares outstanding. The number of shares has increased by 37.77% in one year.
| Current Share Class | 139.66M |
| Shares Outstanding | 139.66M |
| Shares Change (YoY) | +37.77% |
| Shares Change (QoQ) | +5.01% |
| Owned by Insiders (%) | 2.26% |
| Owned by Institutions (%) | 61.75% |
| Float | 113.21M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 75.95 |
| Forward PS | 118.69 |
| PB Ratio | 4.42 |
| P/TBV Ratio | 4.42 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 53.38 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.03, with a Debt / Equity ratio of 0.01.
| Current Ratio | 4.03 |
| Quick Ratio | 4.03 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -48.42% and return on invested capital (ROIC) is -33.58%.
| Return on Equity (ROE) | -48.42% |
| Return on Assets (ROA) | -24.72% |
| Return on Invested Capital (ROIC) | -33.58% |
| Return on Capital Employed (ROCE) | -45.80% |
| Weighted Average Cost of Capital (WACC) | 8.50% |
| Revenue Per Employee | $114,616 |
| Profits Per Employee | -$954,274 |
| Employee Count | 73 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +222.70% in the last 52 weeks. The beta is 0.78, so ACRS's price volatility has been lower than the market average.
| Beta (5Y) | 0.78 |
| 52-Week Price Change | +222.70% |
| 50-Day Moving Average | 4.25 |
| 200-Day Moving Average | 3.06 |
| Relative Strength Index (RSI) | 52.23 |
| Average Volume (20 Days) | 1,144,646 |
Short Selling Information
The latest short interest is 7.35 million, so 5.26% of the outstanding shares have been sold short.
| Short Interest | 7.35M |
| Short Previous Month | 7.89M |
| Short % of Shares Out | 5.26% |
| Short % of Float | 6.49% |
| Short Ratio (days to cover) | 5.23 |
Income Statement
In the last 12 months, ACRS had revenue of $8.37 million and -$69.66 million in losses. Loss per share was -$0.56.
| Revenue | 8.37M |
| Gross Profit | -55.91M |
| Operating Income | -78.48M |
| Pretax Income | -69.66M |
| Net Income | -69.66M |
| EBITDA | -78.47M |
| EBIT | -78.48M |
| Loss Per Share | -$0.56 |
Full Income StatementBalance Sheet
The company has $105.42 million in cash and $1.99 million in debt, with a net cash position of $188.80 million or $1.35 per share.
| Cash & Cash Equivalents | 105.42M |
| Total Debt | 1.99M |
| Net Cash | 188.80M |
| Net Cash Per Share | $1.35 |
| Equity (Book Value) | 143.65M |
| Book Value Per Share | 1.03 |
| Working Capital | 82.86M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$52.21 million and capital expenditures -$81,000, giving a free cash flow of -$52.29 million.
| Operating Cash Flow | -52.21M |
| Capital Expenditures | -81,000 |
| Depreciation & Amortization | 14,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -52.29M |
| FCF Per Share | -$0.37 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -938.01% |
| Pretax Margin | -832.58% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ACRS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -37.77% |
| Shareholder Yield | -37.77% |
| Earnings Yield | -10.96% |
| FCF Yield | -8.23% |
Analyst Forecast
The average price target for ACRS is $9.67, which is 112.53% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $9.67 |
| Price Target Difference | 112.53% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | 62.40% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ACRS has an Altman Z-Score of -4.98 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -4.98 |
| Piotroski F-Score | 1 |
